European journal of cancer (Oxford, England : 1990)HumansMaleLeuprolideAgedNitriles
Enzalutamide with or without leuprolide in patients with high-risk biochemically recurrent prostate cancer: EMBARK post hoc analysis by age.
Neal D Shore, Ugo De Giorgi, Matko Kalac, Yiyun Tang, Ruslan Croitoru, Matt Rosales, Melissa J Huynh, Igle J de Jong, Christopher P Evans, Flavio M Carcano, Stephen J Freedland
Published: 202610.1016/j.ejca.2025.116110
Abstract
INTRODUCTION: The EMBARK trial demonstrated that enzalutamide ± leuprolide significantly improved metastasis-free survival (MFS) in patients with nonmetastatic castration-sensitive prostate cancer with high-risk biochemical recurrence (hrBCR). This p…
Preview only. Read the full abstract at the source